Hennion & Walsh Asset Management Inc. Sells 12,885 Shares of Boston Scientific Corporation $BSX

Hennion & Walsh Asset Management Inc. decreased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 12.2% in the 2nd quarter, HoldingsChannel reports. The firm owned 93,021 shares of the medical equipment provider’s stock after selling 12,885 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Boston Scientific were worth $3,970,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in shares of Boston Scientific by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after purchasing an additional 1,436,550 shares during the period. State Street Corp boosted its holdings in shares of Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after buying an additional 920,495 shares during the period. Capital World Investors grew its stake in Boston Scientific by 1.9% in the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after buying an additional 502,627 shares during the last quarter. Norges Bank acquired a new position in Boston Scientific in the 4th quarter valued at about $2,199,395,000. Finally, Morgan Stanley raised its holdings in Boston Scientific by 10.8% in the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock valued at $2,189,289,000 after acquiring an additional 2,246,308 shares during the period. 89.07% of the stock is owned by institutional investors.

Boston Scientific Trading Up 2.3%

Shares of BSX opened at $50.42 on Tuesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The firm has a market cap of $73.07 billion, a price-to-earnings ratio of 20.41, a PEG ratio of 1.08 and a beta of 0.56. The business’s fifty day moving average is $45.80 and its 200-day moving average is $60.25.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.Boston Scientific’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its board has approved a stock repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

Insider Activity at Boston Scientific

In other news, Director David C. Habiger bought 2,100 shares of the stock in a transaction on Wednesday, August 5th. The stock was acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward J. Ludwig bought 5,000 shares of the company’s stock in a transaction on Friday, July 31st. The stock was purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders bought 204,322 shares of company stock worth $9,939,221. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Leerink Partners set a $60.00 price target on Boston Scientific in a report on Thursday, July 30th. Bank of America lowered their price objective on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Raymond James Financial reissued an “outperform” rating and set a $57.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. UBS Group reduced their target price on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Finally, The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a research report on Thursday, May 28th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.